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Abstract
Chronic heart failure (CHF or simply HF) is a complex clinical syndrome that involves
more than 2% of the general population and over 10% of the older people. For people
with reduced ventricular function (the classical HFrEF phenotype), the guideline-
directed medical therapy (GDMT) (e.g., Ace-inhibitors, beta-blockers, diuretics,
rehabilitation or implantable ventricular devices) demonstrated to be efficacious in
reducing hospitalisations and prolonging survival. Vice-versa, the HF with preserved
ejection fraction (diastolic HF or HFpEF phenotype) is a much more complex
syndrome, in which co-morbidities (such as COPD, depression, anemia, and diabetes,
CAD) play a significant role in the decompensation episodes.
As the population ages, the HFpEF phenotype is becoming more frequent and puts
more management problems, since the conventional HF therapy is less efficacious in
the control of symptoms. A multidisciplinary managed approach, based on the
principles of Chronic Care Model, is the most effective tool to ensure best clinical and
social outcomes, for both phenotypes. It is critical that every health worker should use
counselling tools, such as how to recognise characteristics of the disease or early signs
of decompensation and whereby to manage them, the proper use of each drug or how
to modify progressing risk factor, to improve the compliance of the patients toward
the self-management empowerment.
Finally, we propose a plan of care for patients affected with HF, which allows the
integration of multidisciplinary teams and ensures a complete and appropriate
management of the cases, in respect of therapeutic responsibility entrusted to the GP.
Keywords: chronic heart failure, preserved ejection fraction, co-morbidities, integrated
care, Chronic Care Model
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1. Introduction
1.1. Chronic heart failure: Definition and diagnosis
Chronic heart failure (CHF or simply HF) is one of the main causes of death and disability in
the Western world. It is expected that its presence will continue increasing in the future because
of the ageing of the population, the diminution of mortality in the acute phase of coronary
heart disease, the increased prevalence of predisposing clinical conditions (diabetes mellitus,
arterial hypertension, obesity, etc.), as well as the availability of effective drugs in prolonging
the patients’ survival. HF in developed countries is mainly a disease of the elderly population:
the average age of the patients is in fact 75 years [1].
Continuity of care is one of the basic elements for a correct management of HF, both for its
characteristic of chronic disease with more or less frequent exacerbations and for its consid‐
erable clinical variability, which manifests itself with different levels of complexity and not
uniformly progressive in all stages of its evolution, from the very first symptoms of the terminal
stages. This aspect results in a diagnostic difficulty that swings the estimate of prevalence of
the disease from 2 to 6.7% of the general population [2, 3].
In fact, as defined in the Report of the American College of Cardiology Foundation/ American
Heart Association Task Force on Practice Guidelines ‘HF is a complex clinical syndrome that
results from any structural or functional impairment of ventricular filling or ejection of blood’,
but HF should be present as a diastolic dysfunction with a left ventricular ejection fraction
(LVEF) greater than 40%. However, some component of diastolic dysfunction is also common
in patients with LVEF < 40% [1, 2].
NYHA Class Level of Clinical Impairment  
 
No limitation of physical activity. Ordinary physical activity does not cause undue 
breathlessness, fatigue, or palpitations. 
 
Slight limitation of physical activity. Comfortable at rest, but ordinary physical 
activity results in undue breathlessness, fatigue, or palpitations. 
 
Marked limitation of physical activity. Comfortable at rest, but less than ordinary 
physical activity results in undue breathlessness, fatigue, or palpitations. 
 
Unable to carry on any physical activity without discomfort. Symptoms at rest 
can be present. If any physical activity is undertaken, discomfort is increased. 
 
Figure 1. New York Heart Association (NYHA) Heart Failure Symptom Classification System.
The European Task Force on the Diagnosis and Treatment of Acute and Chronic Heart Failure
in 2012 stated that: HF is defined, clinically, as a syndrome in which patients have typical symptoms
(e.g. breathlessness, ankle swelling, and fatigue) and signs (e.g. elevated jugular venous pressure,
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pulmonary crackles, and displaced apex beat) resulting from an abnormality of cardiac structure or
function. The diagnosis of HF can be difficult [4].
On the basis of clinical and structural features of the syndrome, the American College of
Cardiology (ACC) and American Heart Association (AHA) developed a four- stage classifi‐
cation of heart failure [5].
Stage A includes patients who are at risk of developing HF but who have no structural heart
disease at present. Stage B includes patients with structural heart disease but no symptoms.
Stage C includes patients with structural heart disease with current or prior symptomatic heart
failure. Stage D includes patients with severe refractory HF. The previous classification of HF,
based on the NYHA functional scheme (Figure 1), is used to assess the severity of functional
limitations and correlates fairly well with prognosis.
The linkage between ACC/AHA structural staging, NYHA functional classification and
community epidemiology (estimated from the Olmsted County Study for people aged more
than 45 years) is summarised in Figure 2 [5, 6].
Figure 2. Structural, functional and epidemiologic linkages in CHF (for courtesy of Prof. Tang, Assoc. Prof. of Medi‐
cine, Cleveland Clinic Lerner College of Medicine; adapted from [5,6]).
Most patients affected with HF have signs and symptoms of fluid overload and pulmonary
congestion, including dyspnea, orthopnea and paroxysmal nocturnal dyspnea. Patients with
right ventricular failure have jugular venous distention, peripheral oedema, hepatospleno‐
megaly and ascites. Others, however, do not have congestive symptoms but have signs and
symptoms of low cardiac output, including fatigue, effort intolerance, cachexia and renal
hypoperfusion (Table 1).
On physical examination, patients with decompensated heart failure may be tachycardic and
tachypneic, with bilateral inspiratory rales, jugular venous distention and oedema. Patients
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with compensated heart failure will likely have clear lungs but a displaced cardiac apex.
Patients with decompensated diastolic dysfunction usually have a loud S4 (which may be
palpable), rales and often systemic hypertension.
SYMPTOMS SIGNS
TYPICAL MORE SPECIFIC
Breathlessness Elevated jugular venous pressure
Orthopnoea Hepatojugular reflux
Paroxysmal nocturnal dyspnoea Third heart sound (gallop rhythm)
Reduced exercise tolerance Laterally displaced apical impulse
Fatigue, tiredness, increased time to recover after exercise Cardiac murmur
Ankle swelling
LESS TYPICAL LESS SPECIFIC
Nocturnal cough Peripheral oedema (ankle, sacral, scrotal)
Wheezing Pulmonary crepitations
Weight gain (>2 kg/week) Reduced air entry and dullness to percussion at lung bases(pleural effusion)
Weight loss (in advanced heart failure) Tachycardia
Bloated feeling Irregular pulse
Loss of appetite Tachypnoea (>16 breaths/min)
Confusion (especially in the elderly) Hepatomegaly
Depression Ascites
Palpitations Tissue wasting (cachexia)
Syncope
Table 1. Diagnostic symptoms and signs for chronic heart failure (modified from ESC 2012 [4])
In ambulatory patients suspected of having HF, for an initial working diagnosis and treatment
plan, the recommended investigations are [4] electrocardiogram (ECG), echocardiogram and
some haematological investigations:
1. The ECG shows the heart rhythm and electrical conduction, i.e. whether there is sinoatrial
disease, atrioventricular (AV) block or abnormal intraventricular conduction.
2. The echocardiogram provides immediate information on chamber volumes, ventricular
systolic and diastolic function, wall thickness and valve function.
3. Routine biochemical and haematological investigations are also important, partly to
determine whether renin–angiotensin–aldosterone blockade can be initiated safely (renal
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function, sodium and potassium) and to exclude anaemia (which can mimic or aggravate
HF). Other measurements of blood chemistry, such as calcium, liver enzymes, bilirubin,
ferritin and thyroid function, should detect reversible/ treatable causes of HF (e.g.
hypocalcaemia, thyroid dysfunction) and co-morbidities (e.g. iron deficiency).
Natriuretic peptide (BNP, NT-proBNP or MR-proANP) dosage and a chest radiograph (X-
ray) should be useful, but their use for diagnostic purposes is not clearly defined [4].
2. Two phenotypes of chronic HF: reduced or preserved ejection fraction
Most of the evidence supporting interventions in heart failure comes from trials that recruited
patients with left ventricular systolic dysfunction (LVSD). However, about 50% of patients
with chronic heart failure (CHF) have a preserved ejection fraction (HFpEF), which is especially
common in elderly people with highly prevalent co-morbid conditions, and its prevalence is
expected to increase over the next decades [7, 8].
The necessary criteria for diagnosing heart failure with reduced ejection fraction (HF-rEF) or
preserved ejection fraction (HF- pEF or diastolic heart failure) are reported in Table 2. Echo‐
cardiographic evaluation is essential to differentiate the structural abnormalities of the two
phenotypes: HFpEF is usually defined as an ejection fraction equal to or greater than 50%,
while the reduced ejection fraction phenotype (HF-rEF) has an LVEF less than 40%. Both ESC
and ACC/AHA guidelines define a mild left ventricular systolic dysfunction (for EF 35–50%)
that probably represents another phenotype in HF spectrum [8, 9].
Therapies that improve outcome in people with HFrEF have not been found to help people
with HFpEF, further supporting the idea that these two kinds of HF are fundamentally
different [9].
The diagnosis of HF-rEF (reduced ejection fraction)
requires three conditions to be satisfied:
The diagnosis of HF-pEF (preserved ejection fraction)
requires four conditions to be satisfied:
1. Symptoms typical of HF 1. Symptoms typical of HF
2. Signs typical of HF (may not be present in the early
stages and patients treated with diuretics)
2. Signs typical of HF (especially in HF-pEF they may not
be present in the early stages and patients treated with
diuretics)
3. Reduced left ventricular ejection fraction (LVEF): < 40% 3. Normal or only mildly reduced LVEF (35–50%) and leftventricule not dilated
4. Relevant structural heart disease (left ventricular
hypertrophy/left atrial enlargement) and/or diastolic
dysfunction
Table 2. Criteria for diagnosing and differentiate CHF phenotypes (modified from ESC 2012 [4])
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Exercise intolerance is the principal clinical feature in HFpEF. People complain of debilitating
symptoms: the elevation of filling pressures during even modest exercise causes significant
dyspnea and fatigue [7, 9]. NICE guidelines recommend the implementation of exercise
training in HFpEF, but the evidence only evaluates surrogate endpoints such as exercise
capacity and quality of life [10].
3. The guideline-directed medical therapy (GDMT) for chronic heart
failure
The treatments for heart failure become progressively more complex, gradually the clinical
picture worsens (Figure 3) [11]. However, there is a high overall annual mortality (up to 20%),
both for HFrEF or HFpEF [12] particularly in patients with higher NYHA Classes symp‐
toms [13].
General measures, such as the attention to diet and good lifestyle, weight monitoring, patient
education and close medical follow-up, should be done on all patients, while medical therapy
is based on progressive staging and symptoms classification [13].
Figure 3. The progression and complexity of treatments for HF (Modified from [11]).
The term guideline-directed medical therapy (GDMT) has been conjugated by the ACCF/AHA
Task Force on Practice Guidelines to represent optimal medical therapy as defined by ACCF/
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AHA guideline recommended therapies (primarily Class I evidence) [1]. The GDMT for
patients with CHF is resumed in Figure 4 [13].
Even if the recommendations for the use of drugs in HF derived principally from studies that
recruited patients with left ventricular systolic dysfunction (LVSD) (HFrEF), treatments with
same principles are also useful for patients with HFpEF and relevant cardiovascular co-
morbidities, such as hypertension and coronary artery disease (CAD).
Unfortunately, trials using the same medications employed for the treatment of HFrEF have
not shown any significant improvements on survival [8, 12].
ACC/ AHA Stage B C D 
NYHA  Classification I II – III IV 
                     Symptoms a 
 
 
 Treatments 
Asymptomatic 
Symptoms, Current or Prior 
Recurrent or Ongoing 
Rest Dyspnea 
Never 
Hospitalized 
History of 
Hospitalization  
ACEi Yes Yes Yes Yes 
Beta blocker (BBs) Yes a Yes Yes Yes b 
Aldosterone 
antagonist  Yes Yes Yes 
Isosorbide dinitrate-
hydralazine  
Selected 
patients c 
Selected 
patients c 
Selected 
patients c 
Diuretic  If congestion PRN 
If congestion  
PRN Yes 
ARB  PRN d PRN d PRN d 
Digoxin  PRN d PRN d PRN d 
Consider AICD/   
Bi-V pacemaker Selected patients 
e
 Yes Yes Yes 
Abbreviations: ACEi: Angiotensin converting enzyme inhibitor     ARB: Angiotensin receptor blocker 
PRN: as needed    AICD: Automatic Implantable Cardioverter Defibrillator 
Green:  Recommended  Orange: To be considered. 
Notes: 
a
 No explicit evidence of benefit exists for BBs among asymptomatic patients, although many 
patients in this class will have other indications for BBs,  such as coronary artery disease (CAD). 
b BBs may be continued safely for patients with rest dyspnea except in patients with signs of 
congestion or hemodynamic instability. 
c
 The combination of isosorbide dinitrate and hydralazine benefited patients self-reported as African 
American. This combination may be added for patients who remain symptomatic despite therapy 
with ACEIs and BBs and as tolerated without reducing the doses of ACEI or BBs to subtarget doses. 
d
 These interventions may provide symptomatic benefit. If no benefit is perceived, the medications 
may be withdrawn. In the case of digoxin, however, withdrawal may lead to clinical deterioration 
and should be done with caution. Little evidence exists to support the safety of ACEI/aldosterone 
antagonists/ARBs in the same patient. All these agents can increase potassium levels. 
e
  Indication only for asymptomatic patients with ischemic cardiomyopathy. 
 
Figure 4. GDMT for patients with HFrEF (adapted from [13], with permission).
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The only indication to the use of diuretics in chronic HFpEF is for symptomatic relief of acute
or chronic congestion (see Figure 3). The doses of diuretics should be adjusted continuously,
especially when the patient achieves euvolaemia, as further diuresis and dehydration may
decrease preload and cardiac output [8].
The role of the multidisciplinary team in the continuing management of heart failure patients
is pivotal and all the principal guidelines on HF management underline that the complexity
of both the diagnostic process and the therapeutic options, as well as the continuing difficulties
in the diagnosis and management of HFpEF, dictate the recurrent involvement of specialists
[1, 4, 5, 10, 14].
4. Rehabilitation for patients with chronic heart failure
A rehabilitation program has three main components: education, counselling and exercise [10].
Education and counselling are usually incorporated into standard care (see below), while the
role of exercise-based rehabilitation programs in the management of patients with HF is not
completely defined. There is some evidence that cardiac rehabilitation can be useful to improve
functional capacity, exercise duration, health-related quality of life and mortality [1, 4],
particularly in patients with HFrEF [15]. Despite the paucity of direct evidence in HFpEF,
recommendations for rehabilitation should relate to all patients with heart failure without
contraindications, since symptoms and prognosis of patients with HFpEF do not differ
significantly from those with heart failure due to LVSD [7, 10]. A program of rehabilitation
should include patients with symptomatic heart failure, NYHA class II–III, without limitations
for age or sex. A psychological and educational component in the program would assure better
results of the intervention [10].
The optimum exercise ‘prescription’ is uncertain: it ranges from walking to intensive gym-
based activity including resistance and aerobic exercises and exercises within the swimming
pool [4, 10]. In the absence of specific programs for patients with HF, they can also be enrolled
in rehabilitation within other existing cardiac rehabilitation programs (i.e. post-myocardial
infarction and post-cardiac surgery [10]).
Healthcare-based rehabilitation programs are likely to be cost-effective in different popula‐
tions and for different healthcare systems [16].
5. Integrated care for heart failure: The Chronic Care Model
In 2009 Jencks et al [17] demonstrated that heart failure is the most frequent cause of rehospi‐
talisation in Medicare: about 27% of patients discharged with HF were re-admitted within 30
days. The majority of them did not receive a visit from a doctor in the period they stay at home,
after discharge. Discharge planning (i.e. an individualised plan for a patient before the patient
leaves hospital to home) combined with additional post-discharge support can reduce
unplanned readmission to hospital for patients with congestive heart failure [18, 19].
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Evidence suggests that systems of care for patients with HF improve adherence to published
guidelines and clinical outcomes if involve collaborative care with specialists, multidiscipli‐
nary teams (including primary care), with a focus on transitions of care and chronic disease
management [19–23].
All the guidelines on HF management recommend a coordinating care along the continuum
of HF and throughout the chain-of-care delivered by the various services, within the healthcare
system [1, 4, 10, 14]. The natural setting to develop this coordination of care is the Chronic Care
Model (CCM), developed by Wagner and colleagues at the end of the nineties, ‘to bridge the
gap and translate knowledge between evidence-based chronic disease care and actual care
practices’ [24]. The framework, which is centred in primary care, posits six interrelated
elements that are key to high quality chronic disease care: self-management support, rede‐
signing delivery systems, decision support that is system wide, clinical information technol‐
ogy, linkages to community resources and health care system organisation [24].
Recently, the National Heart Foundation of Australia published guidance on policy and system
changes to improve the quality of care for people with chronic heart failure (CHF). The
recommendations point to reduce emergency presentations, hospitalisations and premature
death among patients with CHF [14]. Among the most critical points to overcome there are:
• To ensure equity of access for everyone in disadvantaged areas, including the most vulner‐
able people in socio-economic frailty and the cultural minorities.
• Lack of data and inadequate identification of people with CHF: this leads to ineffectiveness
in measuring outcomes and evaluating the CHF care provided. The development of
mechanisms to promote data linkage across care transitions is essential.
• The enhanced community-based management of CHF, across the empowerment of general
practitioners to lead care.
• Future research activity needs to ensure the translation of valuable knowledge and high-
quality evidence into practice.
The practical application of these principles is included in the recommendation n. 10.2 from
ACCF/AHA guidelines [1]: Every patient with HF should have a clear, detailed, and evidence-based
plan of care that ensures the achievement of GDMT goals, effective management of co-morbid conditions,
timely follow-up with the healthcare team, appropriate dietary and physical activities, and compliance
with secondary prevention guidelines for cardiovascular disease. This plan of care should be updated
regularly and made readily available to all members of each patient’s healthcare team.
A management program for patients with HF (both with reduced and preserved ejection
fraction) needs particular characteristics and components (Figure 5) [4].
Primary care plays a central role in the early identification of HF, transitions to and from acute
care settings, self-care promotion, managing co-morbidities and end-of-life care [23, 25].
However, a recent systematic review of 22 studies has pointed out barriers and facilitators of
implementing the chronic care model in primary care. The inner setting of the organisation,
the process of implementation and characteristics of the individual healthcare providers are
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the major emerging themes. The importance of assessing organisational capacity and needs is
crucial prior to and during the implementation of the CCM, as well as gaining a better
understanding of health care providers and organisational perspective [26].
6. Management of co-morbidities
Frailty and multiple co-morbidities contribute to non-compliance, leading to higher rate of
hospitalisation, rehospitalisation, and ultimately institutionalisation and death [27].
Co-morbidities are important in patients with HF for four main reasons [4]:
1. They may affect the use of some drugs for HF (e.g. in some patients with renal dysfunction
the use of renin–angiotensin system inhibitors may be discouraged);
2. Some drugs, useful for co-morbidities symptoms, may decompensate HF (e.g. NSAIDs
for pain in arthritis);
3. The drugs for different conditions may interact and reduce patient compliance to treat‐
ments: e.g. beta-blockers for HF and beta-agonists for obstructive pulmonary disease;
4. Most co-morbidities are associated with worse clinical status and are predictors of poor
prognosis in HF (e.g. diabetes). Some co-morbidities become subject to treatment (e.g.
anemia) to improve HF.
 
Characteristics  
1. Based on a multidisciplinary approach (cardiologists, primary care 
physicians, nurses, pharmacists, etc.) 
2. Targeted to  high-risk symptomatic patients 
3. Including competent and professionally educated staff 
 
Components  
 Optimized medical and device management 
 Adequate patient education, with special emphasis on adherence and self-care 
 Patient involvement in symptom monitoring and flexible diuretic use 
 Follow-up after discharge (regular clinic and/ or home-based visits; possibly 
telephone support or remote monitoring) 
 Increased access to healthcare (through in-person follow-up and by telephone 
contact; possibly through remote monitoring) 
 Facilitated access to care during episodes of decompensation 
 Assessment of (and appropriate intervention in response to) an unexplained 
increase in weight, nutritional status, functional status, quality of life, and 
laboratory findings 
 Access to advanced treatment options 
 Provision of psychosocial support to patients and family and/ or caregivers 
Figure 5. Management programmes for patients with HF rEF and HFpEF: essential characteristics and components
(adapted from [4]).
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Management of co-morbidities is particularly critical in HF patients with preserved ejection
fraction (the so-called diastolic heart failure or HFpEF) who are older and often affected with
multimorbidity. Patients with HFpEF should be managed with an integrated approach by their
clinical features, addressing underlying co-morbidities known to cause or exacerbate HF [28].
Predisposing and precipitating factors for patients with HFpEF are reported in Table 3.
PREDISPOSING FACTORS PRECIPITATING FACTORS
Advanced age Recurrent ischemia
Female sex Atrial fibrillation
Obesity Renal failure
Hypertension Sepsis
Diabetes
Coronary artery disease
Table 3. Predisposing and precipitating factors for HFpEF in older [28]
Other significant co-morbidities are anemia, COPD, depression, cachexia, gout, and hyperli‐
pidemia [4]. Cardiovascular deaths constitute the majority of deaths in both HFpEF and HFrEF.
However, the proportion of total deaths that are cardiovascular related is higher in HFrEF than
in HFpEF. Conversely, non-cardiovascular deaths constitute a larger proportion of deaths in
HFpEF than in HFrEF [12].
7. Counselling and patient’s empowerment
In chronic illness, patient- centred care (PCC) has a beneficial effect on healthcare professional-
patient concordance regarding treatment plans, patient health outcomes and patient satisfac‐
tion and respects patients’ desired level of involvement in healthcare decisions [30]. Patient
education is focused on the patient’s knowledge about his pathology in making the right
choices about his/her health and not just decisions about the disease, how the disease affects
his/her role in working life, couple or community life [31]. Counselling is the better professional
activity to guide, support and develop the self-management and empowerment both of the
patient and his/her caregiver(s), promoting knowledge and skills to self-care, and stimulating
the ability to make self-choices.
The self-management of chronic disease is essential for optimising health outcomes [32–34]. A
patient-centred approach for CHF management is widely recommended [4,10, 29].
Counselling for CHF management should be focused on simple actions that the patient and /
or the caregiver should practice Table 4.
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A. Characteristics of disease Explain the origin of symptoms;
B. How to identify early signs of
decompensation and what to do with
them
Identify specific signs and symptoms such as increasing fatigue,
worsening dyspnea, appearance of edema;
Daily weight and how to proceed in case of significant increase: contact
details of the care manager, variation of the diet , fluid intake and
diuretics;
C. Instructions on the proper use of each
drug
Explain the rationale for each drug, adverse effects and possible
consequences of a missed dose. Repeat the treatment pattern;
D. Modify risk factors progressing Smoking cessation, glycemic, blood pressure and weight control, motor
activity, alcohol intake;
E. Importance of therapeutic adherence Detect and try to solve any obstacle to the compliance with drug therapy
and lifestyle.
Table 4. Counselling for CHF management: what it is basic for patient and caregiver
8. Integrated care for HF in Italy: a clinical pathway implementation
Patients suffering from HF exhibit different clinic characteristics and care needs depending on
the stage of the disease [5, 11]. The effective management of this disease should be related to
a territorial- and hospital- integrated approach, adapted to the needs of the individual patient
[13, 30, 35, 36].
If the clinical condition is stable, the patient should be followed on an outpatient basis with
the integrated involvement of general practitioners (GPs), nurses and specialists [20, 22, 23,
37–41]. In advanced stages, a more intensive support like the hospital one and/or integrated
home it might be necessary [42–48].
As reported by Vedel and Khanassov [18], transitional care interventions (TCIs) and high
intensity- integrated management models significantly reduce risks of rehospitalisation and
emergency department visits. A long duration (more than 6 months) involvement of GPs,
nurses, and cardiologists is better than a shorter one.
We propose an integrated management care for patients affected with HF, which is based on
the recommendations of the European Society of Cardiology [4]. This model allows the
integration of multidisciplinary teams, ensuring a complete and appropriate management of
the cases, in respect of therapeutic responsibility entrusted to the GP. For each stage of the
ACC/AHA classification [1], functions, activities and tasks of each professional are identified.
In stage A (Table 5) and D (Table 6) the professionals involved, despite being the same, often
operate with different levels of integration, while the real multiprofessional integration occurs
in stages B and C. For this reason the latter are presented in comparison (Table 7).
Finally, in Table 8, a synoptic planning of different programmed activity is reported.
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ST
AG
E A
According to the ACC/AHA classification, patients in stage A are those at risk of developing a structural
heart disease for the presence of cardiovascular risk factors or particular clinical situations, such as:
• Hypertension
• Multi system atherosclerosis
• Diabetes mellitus
• Metabolic syndrome or obesity
• Chronic renal failure
• Prolonged intake of cardiotoxic drugs
• Familiarity of cardiomyopathy
Role and tasks of the professionals
• GP:
◦ Identification of patients with risk factors (e.g. hypertension , diabetes, dyslipidemia,
obesity, sedentary)
◦ Non-pharmacological control of risk factors (e.g. promoting physical activity, weight
control, alcohol consumption)
◦ Setting and titration of personalised drug therapy
◦ Clinical and instrumental follow-up
• Nurses:
◦ Group health education for patients and their families, in particular oriented to the
promotion of healthy lifestyles, proper nutrition and to the adherence of pharmacological
and non-pharmacological therapeutic prescription
• Specialists:
◦ Counselling for patients with problems inadequately controlled by first-level interventions
Table 5. Integrated activities on HF stage A, divided for different professional tasks
ST
AG
E D
Stage D is characterised by patients suffering from HF with frequent exacerbations despite maximal
medical therapy, which may require, in highly selected cases, specialised treatments such as mechanical
support to the circulation, fluid removal procedures, continuous inotropic infusions and heart transplant.
In most cases, however, the patient benefits from a palliative care program (integrated home assistance,
hospice).
Roles and tasks of the professionals
• GP:
◦ Request of hospitalisation when indicated
◦ Adjustment of drug therapy based on therapeutic needs of
individual patient
◦ Clinical and instrumental follow-up based on the clinical
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characteristics of the individual patient, in agreement with the
specialist
◦ Early diagnosis of aggravations of heart failure conditions
with identification of precipitating factors
◦ Evaluation and control of co-morbidities
◦ Activation of integrated home care services and access to
patient’s home
• Nurses:
ST
AG
E D
◦ Periodic evaluation of the parameters (e.g. blood pressure,
cardiac frequency and body weight)
◦ Individual health education of the patient and his family, in
particular verification of patient’s adherence and persistence to
the therapeutic drug prescription, lifestyle and to the correct
alimentation
◦ Periodic telephone contact (from half-yearly to weekly) for
information on taking the drugs, patient’s subjective symptoms,
ability to perform daily activities, changes in the quality of
sleep, changes in body weight, onset of intercurrent diseases
◦ Ambulatory monitoring (from half-yearly to monthly) or
periodic home (from monthly to weekly) for the relief of the
parameters completed by the judgement of the specialist/GP on
patient’s condition
◦ Nursing interventions on related symptoms based on the
personalised care plan
• Specialists:
◦ Request of hospitalisation when indicated
◦ Recognition of aggravation of heart failure conditions with
identification of precipitating factors
◦ Adjustment of drug therapy based on therapeutic needs of
individual patient
◦ Clinical and instrumental follow-up based on the clinical
characteristics of the individual patient, in agreement with GP
◦ Intervention in case of clinical worsening without prompt
response to therapy or any complications
◦ Indication for AICD (automatic implantable cardioverter
defibrillator)
◦ Indication to ultrafiltration
◦ Home access on request of the GP
Table 6. Integrated activities on HF stage D, divided for different professional tasks
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Professionals STAGE B STAGE C
GP
• Identification of patients with stage B:
• clinical evaluation and request of medical
instrumental/laboratory examinations of I level in
presence of signs/symptoms of HF;
• specialist referral for diagnostic confirmation;
hospitalisation when indicated;
• first etiological identification and prognostic
stratification;
• activation of integrated care program and
transmission of patient names in the computer
archive;
• setting and / or adjustment of the therapy;
• personalised clinical and instrumental follow up;
• early detection of exacerbations and diagnosis of
precipitants factors.
▪ Echocardiographic diagnosis of
structural heart disease that does not
present and have not applied in the
past signs and symptoms of HF;
▪ patient with previous myocardial
infarction;
▪ patient with valvular heart disease
at least moderate;
• setting and adjustment of personalised
drug therapy, personalised clinical and
instrumental follow up, according to the
specialist,
• Transmission of the names at the
computerised archive.
Nurse
• health education (patient/family) oriented
to the promotion of healthy lifestyles and
nutrition and pharmacological and non-
pharmacological therapeutic adherence;
• education of the patient to the
self-control of arterial pressure parameters,
cardiac frequency, body weight;
• periodic evaluation of clinical and care
parameters;
• reporting to the general practitioner (GP)
of the patient with relevant issues and
collaboration for the diagnostic and
therapeutic management;
• opening and updating the computerised
clinic folder.
In this stage other resources can be
activated (e.g. anti-smoking centres, gyms
safe) in order to better control the risk
factors.
• health education (patient/family), in particular
pharmacological and non-pharmacological
therapeutic adherence;
• periodic evaluation of clinical parameters such as
arterial pressure, cardiac frequency, body weight;
• monitoring of the patient by phone contact (from
half-year to weekly or as needed – for evaluation
therapy compliance, symptoms, weight, intercurrent
diseases);
• ambulatory monitoring (from semi-annual to
monthly or as needed) or periodic home visits (from
monthly to weekly);
• point of reference for the patient (it is specified that
in the role of disease manager, the nurse becomes a
reference for the patient for issues related to
pathology).
Cardiologist/
internist
• diagnostic/therapeutic confirmation of
structural heart disease;
• setting of clinical and instrumental
follow-up, in agreement with the GP;
consulting for issues not adequately
controlled by the first level interventions;
• indication for hospitalisation for
• clinical, instrumental (echocardiography) and
laboratory evaluation for confirmation/exclusion of
the diagnosis of HF;
• etiological identification of precipitating/favouring
factors and prognostic stratification;
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Professionals STAGE B STAGE C
screening of the causes of myocardial
damage/evaluation of any indications in
non-pharmacological strategies
(revascularisation, correction of valve
disorders, device implant);
• each surgery should have a reference
specialist/ambulatory;
• if the patient has a different reference
doctor, the GP is responsible to verify that
inspections are carried out with similar
cadences to those of the structured path.
• custom setting and / or adjusting drug therapy;
clinical and personal instrumental follow up in
collaboration with the GP;
• programming non-pharmacological therapeutic
procedures (e.g. implantable devices, such as AICD,
CRT-P, CRT-D);
• intervention in case of clinical worsening without
prompt response to therapy or to the appearance of
complications.
Table 7. Integrated activities on HF stages B and C, divided for different professional tasks
Stage
ACC/AHA
and NYHA
grading
Care's goals Action
At least X times/
year follow –up* Notes
3 2 1
STAGE A
Hypertension treatment,
smoking cessation,
dyslepidemia treatment,
promoting regular physical
exercise, abolition of alcohol
and drugs, metabolic
syndrome control
GP visit Unplanned evaluation
Nursing assessment Unplanned evaluation
ECG+ specialistic visit Unplanned evaluation
Echocardiogram
As needed (hypertension and/or
diabetes and/or chronic renal
failure with signs of organ
damage)
to each chemotherapy cycle (in
patients receiving cardiotoxic
drugs)
every 3–5 years in case of family
history of cardiomyopathy
STAGE B
As stage A +
pharmacological therapy of
the structural heart disease,
non -pharmacological
therapy, if indicated
(revascularisation, AICD,
correction of valvulopathy)
GP visit x And as needed
Nursing assessment x Evaluation in alternation at GP
ECG+ specialistic visit x And as needed
Echocardiogram
Every 2 years/as needed (if
clinic modifications/
exacerbations)
STAGE C
NYHA I–II
As stages A + B + reducing
salt intake, heart failure
therapy, implantable devices
GP visit x And as needed
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Stage
ACC/AHA
and NYHA
grading
Care's goals Action
At least X times/
year follow –up* Notes
3 2 1
(such as AICD, CRT-P, CRT-
D) when indicated
Nursing assessment x
Monitoring of clinical
parameters (blood pressure,
cardiac frequency, weight) in
alternance with GP
ECG+ specialistic visit x And as needed
Echocardiogram As needed (if clinicmodifications/ exacerbations)
Blood tests (blood
count, creatinine, Na
+/K+, glycemia,
transaminases)
x Other surveys according toresearch
STAGE C
NYHA III
As A and B + reducing salt
intake, heart failure therapy,
implantable devices (such as
AICD, CRT-P, CRT-D) when
indicated
GP visit x And as needed
Nursing assessment x
Quarterly monitoring of clinical
parameters (blood pressure,
cardiac frequency, weight) in
alternance with GP
ECG+ specialistic visit x
Echocardiogram As needed (if clinicmodifications/exacerbation)
Blood tests (blood
count, creatinine, Na
+/K+, glycemia,
transaminases)
x Other surveys according toresearch
STAGE D
(Home
visits)
Palliative care program or transplantation program
*The follow-up planning should consider the following variables: NYHA class, clinical and therapeutic instability,
repeated hospital admissions, echocardiographic features and exam values.
Table 8. Managed planning for integrated assistance in all HF stages
9. Conclusions
To be effective, an integrated assistance program for the patient with heart failure needs the
continuous cooperation of the multidisciplinary team. Integrated care programs have defini‐
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tively demonstrated a significant reduction in mortality, hospital admissions and readmis‐
sions, as well as visits to the emergency department [49].
However, lack of communication between hospital and primary care seems to be the principal
critical issue in the continuity of care, both for hospital discharge or for the specialist outpatient
report [18, 37].
The general practitioner (GP), with the nurses’ collaboration, should manage patients with
stable conditions with periodical checks focused on the active involvement of the patient, the
constant adaptation of the therapy, the verification of clinical stability, the early detection of
worsening of the disease and its causes.
Following every consultation, the health professional should check the patient’s understand‐
ing of what they have been told. They should ask patients with similar questions: To be sure that
I have explained everything correctly, could you explain to me how you will take your medication? or
Can you tell me what you found most important from our conversation? The patients should be able
to explain or demonstrate, using their words, what has just been discussed with them [50].
In patients with advanced disease, the specialist monitoring must be flexible, and the consul‐
tation should provide clear indications, preferably written, to the patient and family members
on when to request the intervention of GP and on signs/symptoms of destabilisation that
require specialist advice (Table 9).
Information sending by the GP (patient’s
summary)
Specialist outpatient report
• Current therapy regimen • Objectivity at visit time and disease stability
• Patient’s compliance level • Stratification of the risk of events after instrumental tests
• Adverse drug events (if any) • Prescribed treatment with any eventual change compared with the
previous treatment and Indications for drug titration
• Major recent intercurrent events,
also about co-morbidities
• Evaluation of the presence of co-morbidity about instrumental/
laboratory outcomes
• Results of blood tests (e.g. renal function
monitoring)
• Program of specialistic follow-up and indications of instrumental/
laboratory controls
• Indication and contents of specific training activities directed to the
patient and caregiver(s), about the disease, therapy set, and principles of
self-management
• Preferential telephone contacts to communicate with the centre for
acute problems
Table 9. Fundamental aspects of the communication between specialist/general practitioner (GP) in the follow-up of
patients with heart failure
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To standardise multidisciplinary dialogue and assess the effectiveness of clinical pathway, the
local health authorities should organise recurrent multiprofessional audit on data collected
locally and training on path troubles and care results.
A challenge for the future assistance to the patient with heart failure would be the diagnosis
and management of the HF with preserved ejection fraction (HFpEF). As a matter of fact,
HFpEF is predicted to be the dominant phenotype of heart failure in the next decade, and the
principal intervention is to identify and treat risk factors and co-morbidities associated, first
of all, arterial hypertension.
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